NCT00457899

Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective Disorder

RAPID-An Open-Label Randomized, Multicenter Phase IIIb Study to Evaluate the Efficacy and Tolerability of Quetiapine IR (Immediate Release), Over 14 Days, in Acute Schizophrenia/Schizoaffective Disorder (Rapid Versus Conventional Titration)

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 234 (estimated)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether increasing the amount (dose) of quetiapine IR (immediate release formulation) more rapidly than conventional dose increases, improves the control of symptoms as measured by the Positive and Negative Syndrome Scale (PANSS) - a psychiatric assessment scale that measures both positive and negative symptoms - in patients with acute schizophrenia or schizoaffective disorder.

Conditions

• Schizophrenia
• Schizoaffective Disorders
• Psychotic Disorders

Interventions

Type	Name	Description
DRUG	Quetiapine IR (Immediate Release)	oral

Timeline

• Start date: 2007-07-01
• Completion: 2007-09-01
• First posted: 2007-04-09
• Last updated: 2007-11-27

Locations

12 sites across 1 country: United Kingdom